Updated Rezatapopt Monotherapy Interim Data From Ongoing PYNNACLE Ph 2 Trial Across Multiple Solid Tumors With a TP53 Y220C Mutation Announced
“We are pleased to share these updated results from the pivotal portion of the ongoing PYNNACLE trial, which continue to enhance our understanding about the potential of rezatapopt to deliver deep and durable responses in patients with limited targeted treatment options. The improvements in overall response rates and median duration of response across all cohorts and specifically in the ovarian cancer cohort are encouraging and further support the potential of rezatapopt to meaningfully impact outcomes for patients with TP53 Y220C mutated advanced tumors,” said Deepika Jalota, Pharm.D., Chief Development Officer of PMV Pharma. “We remain on track to submit an NDA in the first quarter of 2027 for platinum-resistant/refractory ovarian cancer, while continuing to generate additional data to support our broader regulatory strategy.”
Share:
More News
“We are pleased to evaluate the clinical combination of IDE892 with RG6505 in MTAP-deleted RAS-mutant PDAC,” said Yujiro S. Hata, President and Chief Executive Officer, IDEAYA Biosciences. “This collaboration aligns with our broader clinical strategy to evaluate rational combinations with assets in our MTAP-deletion portfolio, and there remains especially high
“In the first reported data from the clinical combinations of our PRMT5 inhibitor vopimetostat and RAS(ON) inhibitors, we saw extremely encouraging early results, with 92% of patients with PDAC in the vopimetostat plus daraxonrasib arm achieving an objective response, supporting the preclinical data showing synergistic activity of PRMT5 + RAS
“Non-small cell lung cancer is the most prevalent lung disease with more than 8,000 patients in the U.S. diagnosed each year with KRAS G12D-mutations. Receiving Fast Track designation for VS-7375 reinforces both the significant unmet need and the potential of VS-7375 to improve outcomes for patients with KRAS G12D-mutated lung
“KRAS has notoriously been considered an undruggable target and patients with KRAS-driven cancers continue to face limited treatment options with survival measured in months, not years,” said John Reed, M.D., Ph.D., Executive Vice President, Innovative Medicine, Research & Development, Johnson & Johnson. “We believe the proprietary Firelink™ platform will overcome